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Summary 
We have identified in rabbits two hepatic forms of T669 peptide kinases that are very strongly 
activated after systemic injection with the inflammatory cytokiue interleukin 1 (ID1). The T669 
peptide contains a major phosphoryhtion site of the epidermal growth factor receptor, threonine 
699 and is a substrate for mitogen-activated protein (MAP) kinases. The kinases were purified 
to homogeneity and corresponded to 50- and 55-kD proteins on sodium dodecyl sulfate-poly- 
aerylamide gel electrophoresis.  Amino add sequencing of 12 tryptic peptides of both kinases 
identified them as p54 MAP kinase or. This kinase belongs to the novel family of stress-activated 
protein kinag's. This is the first evidence of IL-1 activating a spedfic protein kinase in vivo. 
I 
L-1 is a major inflammatory hormone. It is produced at 
sites of injury or infection where it causes leukocyte ac- 
cumulation, cytokine production, and resorption of connec- 
tive tissue matrix. If it enters the circulation it induces the 
acute phase response and fever (1). 
Its actions are mediated by the 80-kD (type I) receptor 
(2,  3),  but  the intracellular signaling pathways by which 
receptor triggering causes cellular responses are not yet clearly 
defined. There is rapid increase in phos~phorylation of certain 
cellular proteins caused by induction ot protein serlne/threo- 
nine kinase activity. Some of the enzymes involved have been 
identified. For example, components of the growth factor- 
regulated pathway,  the p42/p44 mitogen-activated protein 
(MAP) 1 kinases and their activator, MAP kinase kinase, are 
stimulated in some cdls (4-6). 
A second type of MAP kinase, p54, has been purified and 
recently cloned (7). It is activated by stressful stimuli (e.g., 
heat, protein synthesis inhibition, and UV light) and the 
cytokine TNF. Three very closely related cDNAs (o~,/~, 3~) 
were identified that were '~50%  homologous to p42/p44 
MAP kinases, p54 and p42/p44 MAP kinases phosphorylate 
a similar range of substrates upon serine or threonine in the 
context of proline, and both depend for their activity upon 
phosphorylation of nearly adjacent  threonine and tyrosine 
residues  (8).  The intervening glutamate residue found in 
1 Abbreviations used in this paper: DTT, dithiothreitol; EGF, epidermal 
growth factor; GST, glutathione  S-transferase; MAP, mitogen-activated 
protein; MAP-2, microtubule-associated  protein 2; MBP, myelin  basic 
protein; FFP, protein phosphotyrosine  phosphatase. 
p42/p44 MAP kinases is rephced by a proline residue in p54. 
A consequence of this is that p54 is not activated by MAP 
kinase kinase. 
We recently purified an l'L-l-activated  kinase from KB ceils 
that phosphorylated a MAP kinase substrate, a synthetic pep- 
tide (T669) containing the sequence around threonine 669 
of the epidermal growth factor (EGF) receptor.  Its proper- 
ties suggested it could be a truncated form of p54 MAP ki- 
nase, but we were unable to obtain sufficient quantities for 
amino acid sequencing (9).  We have now investigated the 
possibility that this or similar enzymes may be activated in 
a large organ such as the liver of a cytokine-injected animal. 
Such experiments provide direct evidence of which enzymes 
are activated in vivo (we have found cell lines to vary in the 
pattern of kinases  activated  by IL-1)  and yield quantities 
sufficient for precise identification by amino acid sequencing. 
Materials and Methods 
Materials.  Human recombinant Ibl ~ and PP2A were prepared 
as previously (9). The cDNA of the truncated jun protein com- 
prising amino acids 5-89 was a kind gift of Dr. J. R. Woodgett 
(The Ontario Cancer Institute, Toronto, Canada). It was expressed 
and purified from Escherichia coli as glutathione S-transferase (GST) 
fusion protein as described  elsewhere (10). Microtubuh associated 
protein 2 (MAP-2) was purified from porcine brain (11). Protein 
phosphotyrosine  phosphatase  (PTP) 1B was given by Dr. N. Tonics 
(Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). An- 
tiphosphotyrosine  mAb 4G10 and 3'-ATP-Sepharose  were from Up- 
state Biotechnology Inc. (Lake Placid, NY).  Peroxidase-coupled 
rabbit anti-mouse IgG was from Dako (High Wycombe, Bucks, 
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quence  around  T 669  of the  EGF  receptor was  synthesized  at 
Babraham  Institute.  3t-[32p]ATP (3,000  Ci/mmol)  was  from 
Amersham International (Amersham, Bucks, UK). Myelin basic 
protein (MBP), E64, aprotinin, pepstatin, PMSF, and all other chem- 
icals  were  from  Sigma  (Poole,  UK).  Okadaic  acid  was  from 
Calbiochem-Novabiochem Ltd. (Nottingham, UK) FFQ-, FFS-, 
and phenyl-Sepharoses were from Pharmacia (Milton Keynes, UK). 
The agarose coupled to blue dye no. 9 (mimetic blue 1 A6XL) 
was from Affinity Chromatography Ltd. (Isle of Man, UK). Hyp- 
norm was from Janssen Pharmaceuticals Ltd. (Wantage, Oxon, UK) 
and Sagatal was from Rhone Merieux (Harlow, Essex,  UK). 
Procedures with Rabbits.  Dutch rabbits (2-3 kg) were sedated 
by injection with 0.2 ml/kg s.c. Hypnorm (0.315 mg/ml Fentanyl, 
and 10 mg/ml Fluanisone). II:1 (5/~g/kg) in PBS at a concentra- 
tion of 50/~g/ml,  or PBS alone,  was injected intravenously and 
8 rain later, the rabbits were killed by injection of Sagatal (pen- 
tobarbitone sodium urethane, 100 mg/kg). Livers were rapidly re- 
moved and put on ice, before being homogenized or alternatively 
frozen in liquid nitrogen and stored at  -80~ 
Buffers. We used the following buffers: A: 20 mM Tris, pH 8.5, 
20 mM/3-glycerophosphate, 50 mM NaF, 0.1  mM Na3VO4, 2 
mM dithiothreitol (DTT), 0.5 mM EGTA, and 0.5 mM EDTA; 
B: 20 mM Tris, 0.1 mM EGTA, and 2 mM DTT; C: 20 mM MES 
(2-[N-Morpholino]ethane sulfonic acid), pH 5.9, 20 mM ~-glycero- 
phosphate, 0.1 mM Na3VO4, 10 mM NaF, 2 mM DTT, 0.5 mM 
EGTA, and 0.5 mM EDTA; D: 20 mM Hepes, pH 7.0, 10 mM 
NaF,  0.1  mM  Na3VO4,  2  mM DTT,  and 0.5  mM  EGTA;  E: 
20 mM Tris, pH 7.4, 0.1 mM EGTA, 2 mM DTT, 0.2 mM NaC1, 
and 0.05% Brij35;  and F: 20 mM Tris, pH 7.4, 2 mM DTT, and 
0.05% Brij35. 
Preparation of Liver Extracts.  80-100 g of  liver was homogenized 
in 500 ml of buffer A including 10/~M E64, 10/~g/ml aprotinin, 
1  /~M pepstatin,  and  1 mM PMSF  using  a  Politron  |  blender 
(Kinematica AG, Littau, Switzerland). The homogenate was cen- 
trifuged at 20,000 g for 1 h at 4~  and the supernatant faltered 
(8 #m). 
Purification ofT669 Kinases.  5-20 g of supernatant protein was 
loaded on to a 220-ml column of  Fast Flow Q-Sepharose equilibrated 
in buffer A containing 0.1 M NaC1. Proteins were eluted with a 
linear gradient (250 ml/h) from 0.1-0.6 M NaC1 in 2,400 ml of 
buffer A. Active fractions (made 1 M NaC1) were loaded onto a 
40-ml phenyl-Sepharose column equilibrated in buffer B containing 
1 M NaC1. The column was washed in that buffer and all the T669 
kinase was eluted by buffer B including 50% ethylene glycol. This 
material was made 20 mM with MES, pH 5.9, and loaded onto 
a 10-ml S-Sepharose Fast Flow column equilibrated in buffer C. 
The T669 kinase flowed through and was made 20 mM "Iris, ad- 
justed to pH 8.5. It was loaded onto a MonoQ HR 10/10 column 
equilibrated in buffer A, and.was eluted with a linear gradient from 
0 to 0.5 M NaC1 in 450 ml. Fractions (4 ml) were assayed for T669 
kinase. The two peaks of activity obtained were pooled separately 
and dialysed overnight against  buffer D  at 4~ 
The later eluting kinase (peak II) was loaded onto a 1-ml column 
of blue agarose equilibrated in buffer D. This was eluted with a 
linear gradient from 0 to 0.35 M NaCI in 24 ml at a flow rate 
of I ml/min. Kinase-containing fractions were pooled and concen- 
trated to 0.5-0.8 ml by ultrafiltration (Centricon 10, Amicon Ltd., 
Stonehouse, Gloucs, UK). The sample was than chromatographed 
on a Superose  12 column equilibrated in buffer E. The enzyme 
eluted in one peak and was diluted fivefold in buffer B and made 
20 mM with MgC12. It  was  then loaded onto a 3.5-ml ATP- 
Sepharose  column equilibrated in buffer B  containing 20  mM 
MgC12. After washing the column,  the kinase  was eluted with 
10 ml equilibration buffer containing 2 mM ATP. It was finally 
loaded onto a MonoQ HR 5/5 column equilibrated in buffer E. This 
was eluted with a linear gradient (55 ml at 1 ml/min) from 0 to 
0.7 M  NaC1. 
The smaller peak of T669 kinase (peak I) eluted from MonoQ 
HIL 10/10 was purified further using buffers and chromatography 
conditions identical to those described above except that material 
from four purification runs (e.g., four livers) that had been carried 
through the five initial steps was pooled, and the final sequence 
of chromatography steps was ATP-Sepharose,  MonoQ HR 5/5, 
and Superose  12. 
The first three purification steps were carried out at 4~  and 
reaction mixtures of the kinase assays separated  on gels because 
of high background phosphorylation. Subsequent purification was 
at room temperature and reaction mixtures separated on P81 paper. 
Purified proteins were run on SDS-PAGE (12), and stained with 
silver or Coomassie Brilliant Blue, or Western blotted, stained for 
phosphotyrosine, and detected by chemiluminescence (9). 
Total protein was measured by the method of  Bradford (13). Con- 
centration of pure proteins was estimated from stained SDS-PAGE. 
Purified enzymes were kept at 4~ 
Kinase Assays.  The assays were done in a reaction mixture (15 
/d) of a 5-/,1 sample, 5/~1 T669 Peptide (1.5 mM), or protein sub- 
strates,  5/~1 150 raM, Tris, pH 7.4, 30 mM MgC12, and 60/~M 
ATP  (including  1-2  /zCi  3'-[32p]ATP). Assays were  started  by 
adding ATP and then incubated at 20~  for 20 rain. The reaction 
was terminated by adding 5/~1 SDS electrophoresis sample buffer. 
The phosphorylated substrates  were separated  from the mixture 
by SDS-PAGE. Gels for protein substrates  were 12.5% acrylamide 
for MBP and GST-jun, or 5% for MAP-2. They were stained, dried, 
and autoradiographed. T669 Peptide reaction mixtures were sepa- 
rated on SDS gels containing 16% acrylamide and 6 M urea (14), 
which were autoradiographed  wet. 32p incorporated into substrates 
was  measured by Cerenkov radiation of excised gel slices. 
Alternatively, the reaction mixture containing T669 peptide was 
spotted onto 2  x  2-cm squares of anion exchange paper (model 
P81; Whatman Inc., Clifton, NJ). The squares were washed three 
times  in  30%  CH3COOH  and  0.5%  H3PO4,  once in  EOH, 
dried, and Cerenkov counted. Background phosphorylation of reac- 
tion mixtures from which substrate was omitted was measured and 
subtracted. 
Treatment of Kinases with Phosphatases.  5/zl of kinase was in- 
cubated with 2.5 t~l PP2A (30 mU/ml) or 2.5/d PTP1B (100/~g/ml) 
in 20 mM Tris, pH 7.4, 0.1 mM EGTA, 2 mM DTT, and 0.05% 
Brij35 at 30~  for 30 min. 2.5/~1 of either okadaic acid (20/~M) 
to inhibit PP2A, or Na3VO4 (2 mM) to inhibit PTP1B was then 
added for an additional 10 min. Phosphorylation was then carried 
out on T669 peptide as described in the previous section. To show 
that inactivation was due to phosphatase,  parallel assays were car- 
fled out in which 5 #1 of T669 kinase was incubated either with 
2.5/~1 phosphatase that had been inactivated for 10 rain with 2.5 #1 
inhibitor, or with buffer alone. 
Protein Digestion, Peptide Separation, and Amino Acid Sequencing. 
After separation by SDS-PAGE, proteins were detected by staining 
with Coomassie Blue and excised. Gel pieces were digested with 
trypsin and applied directly to a tandem HPLC separation using 
2.1 mm AX-300 anion exchange and OD-300 reverse phase columns 
on a Hewlett-Packard 1090M with diode array detection. Peak frac- 
tions were collected during elution with a linear acetonitrile gra- 
dient in 0.1% TFA and sequenced using fast cycle automated Edman 
chemistry on a protein sequencer (model 477A; Applied Biosystems 
Ltd., Warrington, UK) modified as described (15). 
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Figure  1.  Hepatic  T669  kinase  activity  in 
rabbits is increased after injection of IL-1. Liver ex- 
tracts from two rabbits injected with II>1 for 8 min 
or vehicle alone were prepared from 2 g of tissue, 
normalized for protein, and chromatographed on 
a  2-ml  FFQ-Sepharose column as  described in 
Materials and Methods. Proteins were ehted with 
a linear salt gradient from 0 to 0.5 M  NaC1, and 
aliquots assayed for T669 kinase activity  as de- 
scribed. Reaction mixtures were separated  on SDS- 
PAGE. The gels were also autoradiographed and 
the T669 peptide phosphorylation quantitated as 
described. 
Results 
Hepatic T669 Kinase Activity Is Increased in Livers of  Rabbits 
After Injection oflL-1.  Cytosolic preparations were made from 
livers removed from rabbits 8 min after intravenous injection 
of IL-1 or vehide,  as described in Materials and Methods. 
Equal aliquots of these were chromatographed on a small FFQ- 
Sepharose column duted with a salt gradient. Fig.  1 shows 
a resuh representative of three pairs of animals. The fractions 
from the IL-l-treated animal contained T669 kinase activity 
eluting  as a broad peak between 100 and 250 raM NaC1, 
There was a 10-fold increase in active material in these frac- 
tions in comparison with those from an animal injected with 
vehicle alone. 
Two T669 Kinases Can Be Purified  from Livers of  lL-l-treated 
Rabbits.  T669 kinase was purified from extracts of livers of 
1L-l-treated animals by successive chromatography on FFQ- 
Sepharose, phenyl-Sepharose, and FFS-Sepharose as described 
in Materials and Methods.  The active material was then ap- 
plied to a MonoQ HR10/10 column and two forms of en- 
zyme were separated by elution  with a salt gradient.  Peak 
I eluted at around 100 mM NaC1, peak II at around 150 mM 
NaC1 (Fig. 2). Peak II contained about two thirds of the ac- 
tivity recovered. Both peaks were further purified by five ad- 
ditional chromatography steps. The purification of peak I en- 
zyme is summarized in Table 1. About 5/~g of protein kinase 
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Figure 2.  Livers  of IL-l-treated animals con- 
rain two T669 kinases. T669 kinase purified 
on FFQ-Sepharose, phenyl-Sepharose,  and FFS- 
Sepharose from one liver was chromatographed 
on a MonoQ HRIO/10 column as described 
in Materials and Methods. Aliquots of the frac- 
tions were assayed for T669 kinase activity and 
reaction mixtures separated on 1)81 anion ex- 
change paper and 32p incorporation into the 
peptide quantitated as described. Table  1.  Purification  of Peak I  of T669 Kinase 
Volume  Protein  Activity  Sp act  Purification (-fold)  Yield 
Extract 
Q-Sepharose 
Phenyl-Sepharose 
S-Sepharose 
MonoQ 
HR 10/10 
Blue-dye 
ATP-Sepharose 
MonoQ 
HR 5/5 
Superose 12 
ml  mg  ctrm  x  10 -~  (cpm  +  mg)  x  10 -3  % 
1,460  34,398  .... 
1,535  4,411  687  156  -  100 
413  2,052  1,260  614  4  183 
473  618  1,255  2,030  13  182 
52  2.69  262  97,398  623  38 
12.5  1.2  59  49,167  315  9 
17  0.1  73  730,000  4,677  11 
7  0.02  26  1,300,000  8,329  4 
2.5  0.005  20  4,000,000  25,628  3 
T669 kinase activity  from livers of IL-l-treated rabbits was purified over the first four steps. Peak I T669 kinase eluted from MonoQ HR 10/10 
from four livers was pooled and purified as indicated through the subsequent steps. See Materials and Methods for details. 
was obtained from four livers. The increase in specific ac- 
tivity over the material from the first anion exchange step 
was 25,000-fold. Peak II enzyme was purified in a similar 
manner (Table 2). About 3/zg of enzyme was obtained from 
one liver,  representing about 30,000-fold purification from 
the first step. 
In view of the likely relationship of these enzymes to MAP 
kinase they were treated with PP2A or PTP1B. Both were 
inactivated  by  either  phosphatase  (Fig.  3)  and  this  was 
prevented by okadaic acid or vanadate, respectively. These 
findings suggested that the enzymes were activated by dual 
phosphorylation of serine/threonine and tyrosine. To iden- 
tify the kinase of peak I aliquots of active fractions from the 
final Superose 12 column were separated on SDS-PAGE, trans- 
ferred to nitrocellulose membrane, stained for protein, and 
probed with an antibody to phosphotyrosine. One phospho- 
tyrosine-containing  band (Hg. 4 C) corresponding to a 50-kD 
protein band (Fig.  4 B) coeluted with the enzyme activity 
(Fig. 4 A): this protein was therefore identified as the kinase. 
In the case of peak II, fractions from the final MonoQ column 
were separated on SDS-PAGE in two duplicate patterns: one 
half of the gel was silver stained whereas the other was blotted 
and probed with antibody to phosphotyrosine. The enzyme 
activity (Fig. 5 A) coduted with a phosphotyrosine-cont~ining 
55-kD protein band (Fig. 5 B and C). This band was there- 
fore identified as the peak II T669 kinase. 
Table 2.  Purification  of Peak II of T669  Kinase 
Volume  Protein  Activity  Sp act  Purification (-fold)  Yield 
ml  mg 
Extract  500  6,875 
Q-Sepharose  485  752 
Phenyl-Sepharose  73  234 
S-Sepharose  93  98 
MonoQ 
HR 10/10  28 
Blue-dye  10 
Superose 12  2 
ATP-Sepharose  14 
MonoQ 
HR5/5  6 
cpm  x  10 -6  (c?m  +  mg)  x  10 -~  % 
152  202  -  100 
168  718  4  111 
237  2,418  13  156 
6.4  92  14,375  77  61 
2.75  128  46,545  249  84 
0.6  30  50,000  267  20 
0.06  28  466,667  2,492  18 
0.003  17  5,666,667  30,260  11 
T669 kinase activity  from the liver of an IL-l-treated rabbit was purified over four chromatography  steps. Peak II from MonoQ HR 10/10 chro- 
matography was further purified as indicated. See Materials and Methods for details. 
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Substrate Specificity of  p50 ancl  p55 T669 Kinase  The ability 
of the enzymes to phosphorylate four MAP kinase substrates 
is shown in Fig. 6. Both phosphorylated T669 best and were 
least active against MBP. The enzymes phosphorylated MAP-2 
or GST-c-Jun (amino acids  5-89)  more rapidly than MBP. 
The  ranking  order  for  both  enzymes was  T669>MAP- 
2>MBP>GST-c-Jun (amino acids  5-89). 
Amino Acid Sequencing of  Peptides Identifies  p50 and p55 T669 
Kinase as Forms of  lo54ot MAP Kinase.  Purified enzymes were 
excised from SDS-PAGE and five tryptic peptides from pS0 
and seven from p55 were obtained and sequenced (Table 3). 
All were identical with the published sequence of the ot form 
of p54 MAP kinase.  Peptides, 3, 5, 6, and 7 were obtained 
from pS0, peptides 1 and 4 were only recovered from p55. 
The sequences of some of these peptides show one or two 
differences in amino acids between the oe and/5 and 3" forms. 
Inspection of the sequences of peptides 2-6 show unequivo- 
cally that the small enzyme is a form of p54 oL, rather than 
3  or'),. 
Discussion 
The experiments provide the first direct evidence of IL-1 
rapidly activating a protein kinase in a tissue in vivo.  The 
two forms of enzyme that were purified accounted for most, 
and possibly all, of the T669 kinase induced by injecting IL-1. 
The amino acid sequences of the peptides, together with the 
biochemical properties of the enzymes, indicate that both are 
ce forms of p54 MAP kinase, rather than p54 3  or 3' (7, 16). 
T669 peptide is a substrate for p42/p44 MAP kinase, which 
IL-1 activates strongly in some cultured ceils (4-6). We were 
surprised that essentially all the enzyme we detected could 
be accounted for by p50 and p55 and there was little evidence 
of any activated enzyme corresponding to p42/p44 MAP ki- 
nase. We also checked MonoQ chromatography fractions from 
liver extracts of unstimulated and IL-1-treated rabbits for their 
activity towards MBP,  which is the substrate preferred by 
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Figure 3.  Both  peak I and peak II T669 kinase  are inacti- 
vated by phosphatases. Pure kinase of peak I (1) and peak II 
(2) were  incubated  with PP2A, or PTP1B, or phosphatase  in- 
activated with okadaic acid or Na3VO4, respectively.  After 
incubation, okadaic  acid  or Na3VO4 was added to the samples 
containing active phosphatase. Kinase  activity was then as- 
sayed  on T669 peptide. See Materials  and Methods  for details. 
p42/p44 MAP kinase.  However, no increase in MBP kinase 
activity was found in any fractions, induding those containing 
p42/p44 MAP kinase as judged by immunostaining (Kracht, 
M., and A. Finch, unpublished observations).  These fractions 
were also tested for MAP kinase kinase by their ability to 
activate a recombinant p42 MAP kinase. No increase in ac- 
tivity was found in the IL-l-stimulated material (Kracht, M., 
and A.  Finch, unpublished observations). 
The recently reported cDNAs of p54 MAP kinases code 
for full-length ol, B, and 3' proteins, and COOH-terminally 
truncated forms of 3  and 3". The truncated 3' form is iden- 
tical to another recently reported kinase, JNK1, which is ac- 
tivated in cells by UV irradiation and, much like p54, phos- 
phorylates  the NH2-terminal  activation domain  of c•un. 
JNK1 had a molecular mass on SDS-PAGE  of 46 kD (17). 
Since we had purified a 45-kD T669 kinase from KB cells 
having properties similar to p54 we wondered if smaller forms 
would correspond to 3 or 3' sequences.  However, in the case 
of the liver,  the smaller enzyme is clearly p54 ol. The p54 
family is not activated by MAP kinase kinase and has its own 
activator(s).  They have been called stress-activated  protein ki- 
nases since they are preferentially stimulated by stress (e.g., 
cycloheximide, heat,  arsenite, and UV radiation), whereas 
mitogens and phorbol esters preferentially activate the p42/p44 
MAP kinase path (7).  IL-1 may also preferentially activate 
p54 in the liver,  but further investigation of this response 
is needed since our observations on the absence of p42/p44 
MAP kinase activation are restricted to a single time point 
after cytokine injection. 
It will be important to establish which pathway is impor- 
tant for which cdhlar responses, and to find out how inflam- 
matory cytokines such as IL-1 and TNF, which are them- 
selves induced by stressful stimuli, activate the stress-kinase 
pathway. More needs to be known about the physiological 
significance of these signaling systems, but it is possible that 
they could be manipulated to interfere with cytokine action 
therapeutically. Figure 4.  Identification of  peak 
I T669 kinase. Aliquots of the most 
active fractions from  Superose 12 
chromatography of  peak I T669 ki- 
nase (A)  were  separated on 10% 
SDS-PAGE and electrophoretically 
transferred  to  nitrocellulose.  The 
blot was stained with Coomassie 
Brilliant Blue (B) and then probed 
for phosphotyrosine with antibody 
4G10 (C). 
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II T669 kinase. The active fractions 
of peak  II  purified  on  MonoQ 
HR5/5 (A) were concentrated  six- 
fold. 80 #1 of each fraction was run 
in two patterns on 10% SDS-PAGE. 
One half of  the gel was stained with 
silver (/3) and the other was blotted 
and probed for phosphotyrosine (C). 
Details  are given in Materials  and 
Methods. 
2023  Kracht et al. Table  3.  Amino Acid Sequencing of Peptides Identifies p50 and p55  T669 Kinases as forms of pS4~ MAP Kinase 
Peptide  Amino acid  Sequence  Protein 
1  73-78  ELVLLK  p55 
ELVLLK 
ELVLMK  B 
ELVLMK  y 
2  193-203  APEVILGMGYK  p50and p55 
APEVILGMGYK 
APEVILGMGYK 
APEVILGMGYK 
3  237-250  VIEQLGTPSAEFMK  p50and p55 
VIEQLGTPSAEFMK  a 
VIEQLGTPCPEFMK  B 
VIEQLGTPCPEFMK 
4  301-308  MLVIDPDK  p55 
MLVIDPDK 
MLVIDPAK 
MLVIDASK 
5  318-327  HPYITVWYDP  p50 ~d  p55 
HPYITVWYDP 
HPYINVWYDP 
HPYINVWYDP 
6  346-353  EHAIEEWK  p50and p55 
EHAIEEWK  a 
EHTIEEWK 
EHTIEEWK 
7  354-358  ELIYK  p50and p55 
ELIYK  a 
ELIYK 
ELIYK  T 
Tryptic peptides from both enzymes were sequenced as described in Materials and Methods. All the peptides were obtained from p55, but only peptides 
2,3,5,6, and 7 were from pS0. The amino acids of the peptides are underlined and are aligned with the corresponding peptides in the published se- 
quences of ~, fl, and 3" rat p54 MAP kinases (7). The position of the peptides within the sequence is indicated by numbering the amino acids. Differ- 
ences in amino acid residues between the or, /3, and 3, forms are shown in boldface type. 
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Figure 6.  Substrate specificity  of  p50 (peak I) and p55 
(peak II) T669 kinase. 5/~i of pure enzyme of peak I (1) 
and peak II (2) was assayed  for 15 rain at 20~  on MAP-2 
(0.3 mg/ml), MBP (0.3 mg/ml),  GST-jun (5-89) (0.17 
mg/ml), and T669 peptide (0.5 mM). The ATP concen- 
tration was 50/~M. Reaction mixtures containing pro- 
tein were separated on SDS-PAGE  and for T669 peptide, 
on P81 anion exchange  paper. 3zp incorporation into sub- 
strates was measured  as described  in Materials and Methods 
and expressed  as a percentage  of T669 peptide phosphory- 
lation.  Peak I  kinase activity  on  T669  was  31,000 
cpm/assay, peak II kinase activity on T669 was 16,000 
cpm/assay. 
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